Effect of the suspension of the J&J COVID-19 vaccine on vaccine hesitancy in the United States.
COVID-19
USA
Vaccine hesitancy
Vaccine safety
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
24 01 2022
24 01 2022
Historique:
received:
24
06
2021
revised:
20
11
2021
accepted:
28
11
2021
pubmed:
15
12
2021
medline:
18
1
2022
entrez:
14
12
2021
Statut:
ppublish
Résumé
On April 13, 2021, U.S. authorities announced an investigation into potential adverse events associated with the Johnson & Johnson (Janssen, J&J) COVID-19 vaccine and recommended "a pause in the use of this vaccine out of an abundance of caution." We examined whether public attitudes toward COVID-19 vaccination shifted after this recommended suspension using an interrupted time series with data from the Census Bureau's Household Pulse Survey, which was fielded bi-weekly between January 6 and April 26, 2021. We found no significant changes in trends of the proportion of the U.S. adult population hesitant about getting a COVID-19 vaccine, but a significant increase in concerns about safety and efficacy of COVID-19 vaccines among the already hesitant population.
Identifiants
pubmed: 34903374
pii: S0264-410X(21)01559-0
doi: 10.1016/j.vaccine.2021.11.085
pmc: PMC8664657
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
424-427Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr SteelFisher's partner is a partial owner of a company that does consulting for Eli Lilly, a pharmaceutical company.